{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-25-015700","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.782679+00:00","generated_at":"2026-05-17T06:17:49.623070+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M","bullets":["$8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.","Refinances ~$1.7M existing debt; net proceeds ~$5.7M after discount, fees, and debt repayment.","Proceeds to accelerate Teverelix (GnRH Antagonist) for AURr and high CV risk prostate cancer (~$6B market).","Optional redemption at any time at face value plus interest; Yorkville may force redemption from equity financings (excluding SEPA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-25-015700","json":"https://secwatch.observer/filing/0001062993-25-015700.json","markdown":"https://secwatch.observer/filing/0001062993-25-015700.md","text":"https://secwatch.observer/filing/0001062993-25-015700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/0001062993-25-015700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:17:49.623070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}